All Updates

All Updates

icon
Filter
Funding
Product updates
Quris raises USD 9 million in seed funding and launches AI platform
AI Drug Discovery
Oct 18, 2021
This week:
M&A
N-able acquires Adlumin for USD 266 million to strengthen cybersecurity offerings
Next-gen Cybersecurity
Today
M&A
Bitsight acquires Cybersixgill for USD 115 million to enhance threat intelligence capabilities
Cyber Insurance
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Generative AI Infrastructure
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Data Infrastructure & Analytics
Today
Product updates
Microsoft launches Copilot Actions for workplace automation
Foundation Models
Yesterday
M&A
Almanac acquires Gro Intelligence's IP assets for undisclosed sum
Smart Farming
Yesterday
Partnerships
Aduro Clean Technologies partners with Zeton to build hydrochemolytic pilot plant
Waste Recovery & Management Tech
Yesterday
Funding
Oishii raises USD 16 million in Series B funding from Resilience Reserve
Vertical Farming
Yesterday
Management news
GrowUp Farms appoints Mike Hedges as CEO
Vertical Farming
Yesterday
M&A
Rise Up acquires Yunoo and expands LMS monetization capabilities
EdTech: Corporate Learning
Yesterday
AI Drug Discovery

AI Drug Discovery

Oct 18, 2021

Quris raises USD 9 million in seed funding and launches AI platform

Funding
Product updates

  • Israeli AI drug discovery company Quris has raised USD 9 million in a seed funding round led by Dr. Judith Richter and Dr. Kobi Richter, pioneers of cardiovascular intervention therapeutics. The round also saw participation from other medical leaders and strategic investors. Simultaneously, the company publicly launched its clinical-prediction AI platform. 

  • The proceeds will be directed toward accelerating the research and development of novel therapeutics, growing its team, and entering into synergistic partnerships. The funds will also be used to test the first hundred or thousand drugs to train the AI platform.

  • Founded in 2019, Quris’ AI platform uses the serial organoid system or “patient-on-a-chip” technology—a small-scale simulation of the human body and organs, which is used to predict a drug’s response and effectiveness in humans. This method is believed to replace mice-testing, expedite the drug development process, and save costs significantly.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.